Clinical trials
Metastatic clinical trials
Below are recruiting metastatic clinical trials, each written for real people, not researchers. We’re tracking 2,369 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05582538RecruitingPhase 2
Ceralasertib plus immunotherapy for advanced triple-negative breast cancer
This Phase 2 trial tests whether a drug called ceralasertib can help the immune system work better, followed by durvalumab plus nab-paclitaxel. It is for people with advanced triple-negative breast cancer whose cancer returned after earlier treatment, including chemotherapy and immune therapy.
Novara, NovaraAges 18 years+ - NCT05601440RecruitingPhase 2
Trial for metastatic breast cancer that resisted CDK4/6 treatment
This Phase 2 study tests treatments guided by blood testing (“liquid biopsy”) in people with hormone receptor–positive, HER2-negative metastatic breast cancer that has progressed after standard CDK4/6 medicine plus hormone therapy. It aims to find a better way to control cancer after the first treatment stops working.
Calgary, AlbertaAges Any age - NCT05610501Recruiting
Ultrasound-guided biopsy for pelvic masses
This study looks at how well an ultrasound-guided needle biopsy (Tru-Cut) can safely collect tissue samples from pelvic masses. It may help doctors confirm diagnoses and guide treatment by improving how biopsies are done in real-world care.
LeuvenAges 18 years+ - NCT05627219Recruiting
Training men to share prostate cancer genetics info
This study tests a program that trains men (especially African American men) to help others understand prostate cancer genetic counseling and testing. It may improve access to this information by using peer support and patient navigation.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05628870RecruitingPhase 1
Testing HRS-1358 for breast cancer that has spread
This early-phase study tests HRS-1358 tablets in people with breast cancer that is locally advanced or has spread. It may help learn whether the drug can control cancer, while also checking safety and how the body handles it.
Beijing, Beijing MunicipalityAges 18–75 - NCT05631249RecruitingPhase 2
Sotorasib for KRAS G12C lung cancer after prior treatments
This Phase 2 trial studies sotorasib, a targeted medicine, in people with non-small cell lung cancer (NSCLC) that has a specific KRAS mutation called G12C. You may be eligible if your cancer has spread or can’t be removed by surgery and has grown again after at least one previous treatment.
LyonAges 18 years+ - NCT05636618RecruitingPhase 1/Phase 2
Targeted radiation for certain receptor-positive tumors
This trial tests a targeted form of radiation made to stick to specific “somatostatin receptor” markers on tumors. It is designed for people with advanced, receptor-positive neuroendocrine tumors or meningioma who may have had prior treatments and need more options.
Jacksonville, FloridaAges 18–90 - NCT05649683Recruiting
Blood immune testing to predict melanoma response to immunotherapy
This study checks how your immune system behaves (through an immune testing process) to see if it can predict how well advanced melanoma will respond to checkpoint inhibitor treatment. It may help doctors choose the right treatment sooner, without guessing.
Nice, Alpes-maritimesAges 18 years+ - NCT05653388Recruiting
Study biomarker testing in metastatic leiomyosarcoma
This trial looks at lab markers (biomarkers) in tumor samples from people with leiomyosarcoma that has spread or can’t be fully removed. It also enrolls people who are receiving certain first-line chemotherapy, and your results may help guide future treatment decisions.
Santa Monica, CaliforniaAges Any age - NCT05655312RecruitingPhase 1/Phase 2
Targeted radiation melanoma treatment with or without nivolumab
This early-stage study tests whether a targeted radioactive drug can shrink advanced melanoma, either alone or along with nivolumab (an immune-activating medicine). You may be eligible if your melanoma shows a specific target on scan imaging and has progressed despite prior melanoma treatments.
Orange, CaliforniaAges 18–90 - NCT05655780Recruiting
Irinotecan care guided by tumor genes and gut bacteria
This study looks at whether a patient’s tumor genetic makeup and gut bacteria activity can predict how well irinotecan-based treatment works and what side effects they might have. It may help personalize treatment to improve survival and quality of life for people with metastatic or unresectable colon cancer.
Maastricht, LimburgAges 18 years+ - NCT05657873RecruitingPhase 2
Targeted radiation for metastatic lung cancer with liver spread
This trial studies whether adding targeted radiation to the liver (small-area, high-precision radiation) can help people with stage IV non-small cell lung cancer. Participants also start standard “anti–PD-1/PD-L1” immunotherapy (with chemotherapy in some cases).
Miami, FloridaAges 18 years+ - NCT05657743Recruiting
Radiation seeds study for advanced pancreatic cancer safety
This trial tests a radiation treatment that places tiny radioactive seeds directly into the tumor to treat advanced pancreatic cancer. It mainly focuses on safety and whether the treatment can be delivered effectively, especially for people who may not be able to have more chemotherapy or surgery.
HolonAges 18 years+ - NCT05660083RecruitingPhase 2
Study of alpelisib plus iNOS inhibitor with nab-paclitaxel
This Phase 2 trial tests whether a combination of medicines can shrink and control HER2-negative metaplastic breast cancer that cannot be removed with surgery (locally advanced) or has spread (metastatic). It may help people whose cancer has specific lab/pathology features, and it also checks safety and how well the treatment works in the body.
Bethesda, MarylandAges 18 years+ - NCT05661461RecruitingPhase 1
Test drug dosing and safety for advanced cancers with liver issues
This Phase 1 study tests different doses of nab-sirolimus to see if it is safe and how the body processes it. It is for people with advanced or metastatic solid tumors who also have moderate liver impairment.
San Antonio, TexasAges 18 years+ - NCT05668962RecruitingPhase 2
Study selpercatinib plus I-131 for RET thyroid cancer that cannot take iodine
This trial tests whether combining a targeted pill (selpercatinib) with a radioactive iodine dose (I-131) can shrink thyroid cancer that has spread and no longer responds to radioactive iodine. It is for RET fusion–positive (genetically driven) thyroid cancers where the cancer cannot reliably absorb iodine anymore.
Washington D.C., District of ColumbiaAges 12 years+ - NCT05678270RecruitingPhase 2
ICP-192 for FGFR2 fusion bile duct cancer that spread
This Phase 2 trial tests a medicine called ICP-192 in people with intrahepatic bile duct cancer that cannot be removed with surgery and has spread. It is for tumors that have an FGFR2 fusion/rearrangement, especially after prior chemotherapy stopped working.
Hefei, AnhuiAges 18 years+ - NCT05679921RecruitingPhase 2
Pazopanib, with or without pembrolizumab, for metastatic soft-tissue cancer
This Phase 2 trial tests pazopanib alone or together with pembrolizumab to slow or shrink metastatic soft-tissue sarcoma after prior chemotherapy. It may help some people by strengthening the anti-cancer effect compared with pazopanib by itself.
SeoulAges 20–80 - NCT05686226RecruitingPhase 2
Trial tests immune cells targeting HPV-16 cancers
This Phase 2 trial tests an immune-cell treatment (E7 TCR T cells) designed to attack cancers caused by HPV type 16. It may help people whose HPV-16+ cancer has come back or not responded to standard treatment.
Bethesda, MarylandAges 18 years+ - NCT05687123RecruitingPhase 1
Adding sunitinib to Lutathera for pancreatic neuroendocrine tumors
This early-phase study tests whether adding sunitinib (a targeted pill) to Lutathera (a radioactive treatment) works better for people with advanced pancreatic neuroendocrine tumors. It also checks safety, since this combination has not been widely studied yet.
Duarte, CaliforniaAges 18 years+ - NCT05693766RecruitingPhase 2
Gene test guides treatment for hormone-positive breast cancer
This trial studies whether a gene-signature test can help guide treatment choices for people with hormone receptor–positive (ER and/or PR) breast cancer that has spread or can’t be fully removed. It may help find the best therapy approach after prior hormone therapy and targeted cancer medicine.
Birmingham, AlabamaAges 18 years+ - NCT05694715RecruitingPhase 1
Test combo treatment for cancers with DNA repair gene mutations
This Phase 1 study tests a combination of medicines (including niraparib and irinotecan) for advanced solid tumors that have specific DNA repair gene changes, such as BRCA1/2 or related defects. It aims to see whether the treatment can shrink tumors and is safe enough to continue studying.
San Francisco, CaliforniaAges 18 years+ - NCT05700461RecruitingPhase 1
Testing a new implant drug delivery device for kidney cancer
This early-phase study tests a new small implant (“IMD”) that can deliver a drug for people with kidney cancer going to surgery. If you qualify, you would get the implant placed through the skin and later have it removed during your operation, along with extra lab checks and genetic testing.
Boston, MassachusettsAges 18 years+ - NCT05702229RecruitingPhase 2
Study of combined medicines for advanced stomach cancer with Claudin18.2
This Phase 2 study tests new combination treatments for advanced stomach or stomach-esophagus junction cancer that cannot be removed by surgery. It may help people whose tumors are positive for a marker called Claudin18.2, which the study uses to choose who can receive the treatment.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic?
- Yes. Clin2 currently lists 2,369 recruiting metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.